{"id":"W3109853980","doi":"10.1016/s0140-6736(20)32531-9","title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"The Lancet","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1800,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Carboplatin; Gemcitabine; Internal medicine; Pembrolizumab; Triple-negative breast cancer; Breast cancer; Oncology; Chemotherapy; Docetaxel; Metastatic breast cancer; Placebo; Taxane; Cancer; Pathology; Cisplatin; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}